Gennex Laboratories Ltd

Gennex Laboratories reported strong financial results for the quarter ending December 2024, with net sales reaching Rs 40.01 crore, an 87.05% year-on-year growth. Profit Before Tax and Profit After Tax also saw significant increases, highlighting the company's robust performance in both sales and profitability.

Gennex Laboratories has faced significant volatility, reaching a new 52-week low and experiencing consecutive losses over the past four days. The stock has underperformed its sector and is trading below all major moving averages, reflecting ongoing challenges in the microcap pharmaceuticals market amid broader industry trends.

Gennex Laboratories has recently adjusted its evaluation, highlighting a significant 83.61% increase in net sales for the quarter ending September 2024. Despite consistent growth over six quarters, challenges in management efficiency and a low long-term growth rate raise concerns about sustained performance, even as financial stability remains strong.

Gennex Laboratories has faced significant volatility, reaching a new 52-week low and underperforming its sector. The stock has seen consecutive losses over three days and a substantial decline over the past year, highlighting challenges within the microcap pharmaceuticals segment amid contrasting market trends.

Gennex Laboratories has reached a new 52-week low of Rs. 13.13, despite outperforming its sector by 2.43%. The stock has reversed a three-day decline but remains below key moving averages. Over the past year, it has declined by 26.53%, contrasting with the Sensex's positive performance.

Gennex Laboratories has reached a new 52-week low of Rs. 13.13, despite outperforming its sector by 2.43%. The stock has reversed a three-day decline but remains below key moving averages. Over the past year, it has declined by 26.53%, contrasting with the Sensex's positive performance.

Gennex Laboratories has reached a new 52-week low of Rs. 13.13, despite outperforming its sector by 2.43%. The stock has reversed a three-day decline but remains below key moving averages. Over the past year, it has declined by 26.53%, contrasting with the Sensex's positive performance.

Gennex Laboratories has reached a new 52-week low of Rs. 13.13, despite outperforming its sector by 2.43%. The stock has reversed a three-day decline but remains below key moving averages. Over the past year, it has declined by 26.53%, contrasting with the Sensex's positive performance.

Gennex Laboratories has recently experienced an evaluation adjustment, highlighting a reassessment of its market position. The company reported significant net sales growth of 83.61% in September 2024, despite facing challenges in management efficiency and a cautious market sentiment reflected in its stock performance over the past year.

Gennex Laboratories, a microcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO due to its low Debt to Equity ratio and concerns about management efficiency. Despite positive short-term results and a Mildly Bullish stock, the company's long-term growth and high valuation may be a cause for concern.

Gennex Laboratories, a microcap pharmaceutical company, has received a 'Buy' rating from MarketsMOJO due to its strong financial performance and positive outlook. The company has a low Debt to Equity ratio, consistent growth in Net Sales, and a bullish trend in its stock. However, there are some risks to consider, such as a low ROE and a premium valuation. Overall, Gennex Laboratories presents potential for future growth and is an attractive option for investors.

Gennex Laboratories, a microcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO due to its low Debt to Equity ratio and concerns about management efficiency. Despite positive short-term results and a bullish stock trend, the company's slow long-term growth and expensive valuation may be a cause for concern.

Gennex Laboratories, a microcap pharmaceutical company, has received a 'Buy' rating from MarketsMOJO due to its low Debt to Equity ratio and impressive growth in Net Sales. The company's cash and cash equivalents are at a record high and its stock is in a bullish trend. However, there are risks such as poor management efficiency and slow long-term growth.

Gennex Laboratories, a microcap pharmaceutical company, has reached a 52-week high on September 19, 2024, with its stock price hitting Rs. 29. It has also seen a slight dip in performance today, falling by 4%. The company's stock is currently trading above its moving averages, indicating a positive trend.

Gennex Laboratories, a microcap pharmaceutical company, has seen a significant increase in its share price, reaching an all-time high on September 19, 2024. The company's stock has been outperforming the sector for the past 11 days and has hit a new 52-week high of Rs.29. Its impressive performance has caught the attention of investors and analysts.

Gennex Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on September 18, 2024. With a consecutive gain of 51.87% in the past 10 days, the company's stock has outperformed the sector and is trading higher than its moving averages. Its remarkable growth of 246.03% in the past year highlights its potential in the pharmaceutical industry.

Gennex Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high of Rs. 27.98 on September 18, 2024. Despite underperforming the sector today, the company has shown impressive growth potential with a 1-year performance of 244.10%. Investors and analysts are closely monitoring its progress in the industry.

Gennex Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on September 17th, 2024. The stock has been on a consecutive upward trend for the past 9 days, with a gain of 50.74%. According to MarketsMOJO, the current call for the stock is 'Hold' and it has outperformed the sector by 5.03%. In the past year, Gennex Laboratories has shown a remarkable performance with a 239.06% increase in its stock price, showcasing its strong potential and growth in the pharmaceutical industry.

Gennex Laboratories, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high of Rs.26.65 on September 17, 2024. The stock has been on a consecutive upward trend for the past 9 days, outperforming the pharmaceutical and drugs sector by 5.18%. Its consistent growth and strong market performance make it a promising player in the industry.